Psoriatic Arthritis

• Testing the safety and efficacy of combining biologic drugs in Rheumatoid and Psoriatic Arthritis Not authorised
  2024-518011-19-00 4
• Testing the safety and efficacy of combining biologic drugs in Rheumatoid and Psoriatic Arthritis Pending
  2024-518011-19-01 4
• IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY. Pending
  2025-521259-21-00 6
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5
• A clinical study of tulisokibart in people with psoriatic arthritis (MK-7240-015) Recruiting
  2025-520997-21-00 4 2026-05-08
• A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with A … Recruiting
  2023-510242-24-00 6 2025-12-01
• A Phase 2, open-label, imaging study to explore the effects of sonelokimab in patients with active psoriatic arthritis or axial spondyloarth … Recruiting
  2024-514504-13-00 4 2025-09-23
• A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis Recruiting
  2024-519291-11-00 4 2025-07-25
• A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting
  2024-513111-27-00 5 2025-06-26
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici … Recruiting
  2024-516219-25-00 5 2025-03-25
• Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patient … Recruiting
  2024-512459-19-00 6 2024-09-13
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos … Recruiting
  2023-508251-39-00 5 2020-09-18
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Recruitment ended
  2024-516213-20-00 5 2025-03-25
• A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Recruitment ended
  2024-511738-11-00 5 2024-12-18
• An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Recruitment ended
  2022-501480-41-00 5 2023-04-06
• Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One … Recruitment ended
  2023-504715-33-00 5 2021-09-27
• Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Recruitment ended
  2023-504716-15-00 6 2021-08-06
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo … Recruitment ended
  2023-505477-33-00 5 2019-06-18
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Recruitment ended
  2023-505478-14-00 5 2019-05-09
• A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended
  2022-501362-22-00 10 2023-04-18
• U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing Ended
  2024-512669-15-00 6 2022-03-24
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su … Ended
  2024-512142-42-00 5 2021-10-05
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien … Ended
  2023-507415-35-00 5 2021-01-15
• Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA). Ended
  2024-511401-40-00 6 2020-03-03

Showing 1–24 of 26 trials